CTNND2 (Catenin Delta 2)

Delta-catenin, a neuronal adherens junction protein implicated in brain development and cancer

Gene Information Card

Symbol CTNND2
Full Name Catenin Delta 2
Gene Type Protein coding
Chromosomal Location 5p15.2
NCBI Gene ID 1501 ncbi.nlm.nih.gov/gene/1501
Ensembl ID ENSG00000169862
UniProt ID Q9UQB3
OMIM ID 604275
HGNC ID 2516
Aliases NPRAP, delta-catenin, neurojungin

Description

CTNND2 encodes delta-catenin, a member of the armadillo/plakoglobin family. It is predominantly expressed in the nervous system and localizes to adherens junctions, where it interacts with cadherins and regulates synaptic structure and function. Delta-catenin is involved in neuronal migration, dendrite formation, and synaptic plasticity. Loss-of-function mutations are associated with intellectual disability and autism spectrum disorder. Altered expression is also observed in various cancers, including lung, breast, and prostate, where it may influence cell adhesion and invasion.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Intellectual disability, autosomal recessive 70 Loss-of-function mutations in CTNND2 disrupt neuronal adhesion and synaptic signaling OMIM #618271
Autism spectrum disorder Rare CNVs and missense variants affecting delta-catenin function ClinVar, PMID: 25217958
Lung cancer Delta-catenin overexpression promotes cell migration and invasion COSMIC, PMID: 23382219
Breast cancer Reduced delta-catenin expression correlates with poor prognosis PMID: 21947058
Prostate cancer Delta-catenin loss linked to increased metastatic potential PMID: 20010872

Expression Profile

Tissue Expression
Tissue nTPM level
Brain 32.5 High
Testis 6.8 Medium
Lung 2.1 Low
Breast 1.5 Low
Prostate 1.2 Low
Cell Line Expression
Cell Line nTPM Notes
SH-SY5Y (neuroblastoma) 28.3 Neuronal model
A549 (lung carcinoma) 4.5 Lung cancer line
MCF7 (breast carcinoma) 2.0 Breast cancer line
PC3 (prostate carcinoma) 1.8 Prostate cancer line
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.226C>T (p.Arg76*) Nonsense Rare Loss of function; associated with intellectual disability
c.1240G>A (p.Gly414Arg) Missense Rare Impaired binding to cadherins; autism spectrum disorder
c.1685_1686del (p.Glu562fs) Frameshift Rare Loss of function; intellectual disability
Amplification Copy number gain 1-2% in lung adenocarcinoma Overexpression; potential oncogenic effect
Mutation functional classification

Loss of Function (LOF)

Nonsense and frameshift mutations (e.g., p.Arg76*, p.Glu562fs) lead to truncated or absent delta-catenin, disrupting neuronal adhesion and causing neurodevelopmental disorders.

Gain of Function (GOF)

Amplification and overexpression in lung cancer may enhance cell migration and invasion, suggesting a potential oncogenic role.

Dominant Negative (DN)

Missense variants (e.g., p.Gly414Arg) may interfere with wild-type delta-catenin function by disrupting cadherin binding, though dominant-negative effects are not fully established.

Gene Ontology (GO)

• cell adhesion • synaptic signaling
• cadherin binding • protein homodimerization activity
• neuron projection development

Pathways

• Cadherin signaling pathway
• Wnt signaling pathway
• Adherens junction

Protein Summary

Delta-catenin is a 1225-amino-acid protein containing 10 armadillo repeats. It binds to the juxtamembrane domain of classical cadherins and links them to the actin cytoskeleton. In neurons, it regulates dendritic spine morphogenesis and synaptic plasticity. The protein is also involved in intracellular signaling, including modulation of Rho GTPases and transcription factors.

Related Products

Product name Cat.No. Species Gene ID
CTNND2 Knockout HEK293 Cell Line EDJ-KQ290 Human 1501 Details Get a Quote
CTNND2 Knockout HeLa Cell Line EDJ-KQ53025 Human 1501 Details Get a Quote
CTNND2 Knockout A-549 Cell Line EDJ-KQ61489 Human 1501 Details Get a Quote
CTNND2 Knockout HCT 116 Cell Line EDJ-KQ69984 Human 1501 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: